Da'an gene: a detection reagent for Ebola virus is currently under development

Source: Investment express announced in the afternoon of Daan gene (002030) with poor performance in the morning on August 5, 2014 The company obtained a registration certificate of medical devices issued by the State Food and drug administration The name of medical devices is "missing alpha thalassemia gene detection kit (PCR fluorescence probe method)." , after which, the stock price soared close to the limit, closing up 7.37% In the evening, the company announced that the "Ebola virus nucleic acid detection kit (PCR fluorescence probe method)" has entered the development stage However, the company said that there are uncertainties in the development results, development cycle and related matters of the development process of the kit, as well as the industrialization and market demand of the kit It is understood that this is the first company in the A-share market to publicly say that it is developing Ebola related reagents Recently, stimulated by the rapid spread of Ebola virus and other news, the concept shares of Bora in the A-share market were fried, and the share prices of several shares, such as Lukang medicine and Rhine biology, soared However, relevant companies have "clarified" this For example, Rhein Bio said that the products currently produced by the company are not related to the drugs and vaccines against the Ebola virus The analysis pointed out that as the first company to publicly admit that it is developing Ebola related reagents, Daan gene's share price will become the leader of the concept stock of Ebola in the future